Clinical Study Results
What adverse reactions happened during this study?
The most common adverse reaction was a decreased count of white blood cells called
neutrophils.
The table below shows the most common adverse reactions that happened in 8 or
more participants. There were other adverse reactions, but these happened in fewer
participants.
Most common adverse reactions during the study
Durvalumab and
tremelimumab with
chemotherapy
Adverse reactions (out of 32 participants)
Decreased count of white blood cells
56.3% (18)
called neutrophils
Decreased appetite 34.4% (11)
Nausea 31.3% (10)
Itchiness 25.0% (8)
Decreased count of blood clotting
25.0% (8)
fragments called platelets
How has this study helped patients and researchers?
This study helped researchers learn more about durvalumab and tremelimumab with
chemotherapy for participants with advanced solid tumors.
Researchers look at the results of many studies to decide which treatments work best
and are safest. This summary shows only the main results from this one study. Other
studies may provide new information or different results.
Further clinical studies with durvalumab and tremelimumab are planned or ongoing.
11